Effects of Hypoxia or Caffeine on 4km Time-trial Morning Cycling.
This study aims to implement a rigorously standardized protocol to investigate the effect of acute (60 min prior) caffeine intake or hypoxia (1000m and 2000m) on 4km time trial performance.
調査の概要
状態
詳細な説明
Time-trial performance is widely regarded as the gold-standard measure of endurance exercise capacity, because successful performance depends on completing a fixed distance in the shortest possible time while effectively regulating pacing strategy and power output. As a result, time-trial performance is considered as one of the most ecologically valid measures of endurance performance in both laboratory investigations and applied sport settings. For many endurance athletes, training and competition frequently occur during the morning due to event scheduling, travel requirements and environmental considerations. However, the morning period is characterised by several time-of-day-related physiological differences that may negatively influence exercise performance. Although systematic reviews have reported substantial variability in the magnitude of diurnal fluctuations in time-trial performance, evidence from well-controlled laboratory studies using fixed-distance protocols under thermoneutral conditions consistently indicates superior performance during the late afternoon or evening. Specifically, improvements in evening performance have been observed across a range of endurance modalities, including 100-m swimming (2.6%), 1-km cycling (2.3%), 4-km cycling (2.6%), 10-km cycling (2.3%), 10-km treadmill running (6.3%), and 16.1-km cycling (3.6%). These findings suggest that morning time-trial performance may be compromised relative to later times-of-day, potentially due to circadian variations in physiological and psychological readiness for exercise. Given that athletes are often required to compete in the morning despite these potential limitations, identifying practical and effective strategies to enhance morning time-trial performance is of considerable interest to athletes, coaches and practitioners seeking to optimise competitive outcomes.
Among the nutritional strategies proposed to improve morning performance, acute caffeine ingestion remains one of the most widely consumed and extensively studied ergogenic aids. Caffeine (1,3,7-trimethylxanthine) primarily exerts its performance-enhancing effects through antagonism of adenosine receptors in the central nervous system, resulting in increased arousal, reduced perceptions of fatigue, and enhanced neurotransmitter activity, including dopamine and noradrenaline. These neurophysiological effects collectively promote wakefulness, attention and central motor drive, thereby facilitating exercise performance. Consistent with these mechanisms, substantial evidence demonstrates that caffeine can improve endurance exercise capacity and time-trial performance across a variety of exercise modalities. Despite the well-established ergogenic effects of caffeine, research examining its efficacy during morning time-trial exercise remains comparatively limited. Interpretation of the available literature is further complicated by several methodological shortcomings, including inconsistent caffeine dosing protocols, inadequate familiarisation procedures and poor control of habitual caffeine intake. Recognising the importance of habitual caffeine consumption as a moderator of physiological and performance responses, recent classification thresholds have been proposed. Categorising individuals as naïve (<25 mg·day-¹), low (25 mg·day-¹ to 0.99 mg·kg-¹·day-¹), mild (1.00-2.99 mg·kg-¹·day-¹), moderate (3.00-5.99 mg·kg-¹·day-¹), high (6.00-8.99 mg·kg-¹·day-¹), and very high (>9.00 mg·kg-¹·day-¹) caffeine consumers. Failure to adequately characterise and control habitual caffeine intake may therefore contribute to the variability observed across studies.
Additional methodological limitations within the existing literature include the absence of both placebo and no-pill comparator conditions, together with insufficient control of key chronobiological variables such as chronotype, sleep quality, habitual training time, and seasonal influences. These factors are particularly relevant given their established influence on exercise performance and their potential to confound assessments of both circadian variation and caffeine-related ergogenic effects. Indeed, recent systematic reviews have identified substantial methodological heterogeneity and risk of bias across chronobiology studies, highlighting the need for more rigorous and standardised experimental designs when investigating time-of-day effects on exercise performance. Consequently, well-controlled studies are required to determine whether acute caffeine ingestion can meaningfully attenuate the physiological disadvantages associated with morning endurance exercise and improve time-trial performance under ecologically valid conditions.
Therefore, the primary aim of the present study was to determine whether the ergogenic effects of acute caffeine (CAFF) ingestion, administered 60-min before exercise, enhance morning 4-km cycling time-trial performance when evaluated when behavioural, methodological and chronobiological confounders were carefully controlled. Habitual caffeine consumers with an intake of >150 mg·day-¹ were recruited to minimise the potential influence of caffeine tolerance and withdrawal, while maximising the physiological response to the administered 300 mg caffeine dose. Secondary outcomes included measures of core and skin temperature, ratings of perceived exertion (RPE), mood-state and physiological responses to exercise.
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:Ben J Edwards, PhD
- 電話番号:01519046238
- メール:B.J.Edwards@ljmu.ac.uk
研究場所
-
-
Merseyside
-
Liverpool、Merseyside、イギリス、L3 3AF
- 募集
- Tom Reilly Building
-
コンタクト:
- Joao Agulhari, BSc
- 電話番号:07379664724
- メール:jpagulhari@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age: 18-30 years old
- Healthy (as determined by the pre-participation questionnaire)
- >2 years aerobically trained individuals
- Consume >150 mg/day of caffeine
- Be able to stick to the retiring and waking schedule of the study as well as no exercise 24 h before and no caffeine.
Exclusion Criteria:
- Age: <18 or >30 years old
- Consume <150 mg/day of caffeine hence caffeine naïve
- Those with a history of significant side effects after the consumption of caffeine.
- Deemed unhealthy/unable to perform exercise determined by PAR-Q
- Shift worker or having travelled out of the UK time zone within the last month of testing
- Muscle related injury or broken/fractured bone within the past 3 years Diagnosed sleep disorder
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:ABCDE
Control, Placebo, Caffeine, 1000m, 2000m, |
300 mg of caffeine ingested in form of 3 100 mg capsules 60 minutes prior to testing.
他の名前:
Placebo capsules made to resemble caffeine. 3 pills the same size as caffeine but filled with maltodextrin (~1.6 g)
他の名前:
No pill control intended to act as a comparator for both Hypoxia and caffeine analysis
他の名前:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 1000 m altitude.
他の名前:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 2000 m altitude.
他の名前:
|
|
実験的:BCDEA
Placebo, Caffeine, 1000m, 2000m, Control, |
300 mg of caffeine ingested in form of 3 100 mg capsules 60 minutes prior to testing.
他の名前:
Placebo capsules made to resemble caffeine. 3 pills the same size as caffeine but filled with maltodextrin (~1.6 g)
他の名前:
No pill control intended to act as a comparator for both Hypoxia and caffeine analysis
他の名前:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 1000 m altitude.
他の名前:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 2000 m altitude.
他の名前:
|
|
実験的:CDEAB
Caffeine, 1000m, 2000m, Control, Placebo, |
300 mg of caffeine ingested in form of 3 100 mg capsules 60 minutes prior to testing.
他の名前:
Placebo capsules made to resemble caffeine. 3 pills the same size as caffeine but filled with maltodextrin (~1.6 g)
他の名前:
No pill control intended to act as a comparator for both Hypoxia and caffeine analysis
他の名前:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 1000 m altitude.
他の名前:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 2000 m altitude.
他の名前:
|
|
実験的:DEABC
2000m, Control, Placebo, Caffeine, 1000m, |
300 mg of caffeine ingested in form of 3 100 mg capsules 60 minutes prior to testing.
他の名前:
Placebo capsules made to resemble caffeine. 3 pills the same size as caffeine but filled with maltodextrin (~1.6 g)
他の名前:
No pill control intended to act as a comparator for both Hypoxia and caffeine analysis
他の名前:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 1000 m altitude.
他の名前:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 2000 m altitude.
他の名前:
|
|
実験的:EABCD
1000m, 2000m, Control, Placebo, Caffeine, Caffeine, |
300 mg of caffeine ingested in form of 3 100 mg capsules 60 minutes prior to testing.
他の名前:
Placebo capsules made to resemble caffeine. 3 pills the same size as caffeine but filled with maltodextrin (~1.6 g)
他の名前:
No pill control intended to act as a comparator for both Hypoxia and caffeine analysis
他の名前:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 1000 m altitude.
他の名前:
Hypoxia intervention ran in a controlled environmental chamber on site. Set oxygen partial concentration to similar levels at 2000 m altitude.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
4km time to completion
時間枠:5 weeks
|
How long does the participant take to complete 4km cycling |
5 weeks
|
|
Average power
時間枠:5 weekas
|
Average power sustained through the 4km |
5 weekas
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cognitive function
時間枠:5 weeks
|
Stroop word-colour interference test |
5 weeks
|
|
Witty
時間枠:5 weeks
|
Light reaction test |
5 weeks
|
|
Memory test
時間枠:5 weeks
|
Rey's Auditory Verbal Learning test |
5 weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- 兆候と症状、呼吸器
- 病理学的状態、徴候および症状
- 徴候と症状
- 低酸素症
- 硫黄化合物
- 有機化学物質
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- カルボン酸
- アルカロイド
- アニリド
- アミド
- アニリン化合物
- アミン
- アセタニリド
- ピリノン
- プリン
- 酸、炭素環
- ベータラクタム
- ラクタム
- セファロスポリン
- チアジン
- フェニルプロピオネート
- キサンチン
- アセトアミノフェン
- カフェイン
- イブプロフェン
- セファレキシン
- 2-(3',4'-dihydroxyphenyl)ethylene sulfate
- 5'-palmitoyl cytarabine
- temoporfin-polyethylene glycol conjugate
その他の研究ID番号
- 261020LJMUSPSREC348
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。